欢迎您加入月均活跃用户100万+的科研社区!如您有任何系统建议,请点此洽谈。
;如有合作推广需求,请近期推荐: | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 热 Springer Nature特刊征稿 | 新 已发表SCI?是时候来Springer出书了! |
![]() |
基本信息 | 登录收藏 | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字![]() | BLOOD BLOOD (此期刊被最新的JCR期刊SCIE收录) LetPub评分 9.8
52人评分
我要评分
声誉 10.0 影响力 9.7 速度 9.5 | |||||||||||||||||||||||||||||
期刊ISSN | 0006-4971 | ![]() 蝌蝌APP,让您与同行交流更轻松
![]() | ||||||||||||||||||||||||||||
E-ISSN | 1528-0020 | |||||||||||||||||||||||||||||
2024-2025最新影响因子 (数据来源于搜索引擎) | 23.1 点击查看影响因子趋势图 | |||||||||||||||||||||||||||||
实时影响因子 | 截止2025年5月19日:22.091 | |||||||||||||||||||||||||||||
2024-2025自引率 | 4.30%点击查看自引率趋势图 | |||||||||||||||||||||||||||||
五年影响因子 | 19.7 | |||||||||||||||||||||||||||||
JCI期刊引文指标 | 3.65 | |||||||||||||||||||||||||||||
h-index | 426 | |||||||||||||||||||||||||||||
CiteScore ( 2025年最新版) |
| |||||||||||||||||||||||||||||
期刊简介 |
| |||||||||||||||||||||||||||||
期刊官方网站 | http://bloodjournal.hematologylibrary.org/ | |||||||||||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||||||||||
期刊投稿网址 | http://submit.bloodjournal.org/ | |||||||||||||||||||||||||||||
期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足BLOOD的语言要求,还能让BLOOD编辑和审稿人得到更好的审稿体验,让稿件最大限度地被BLOOD编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评(1篇) 论文致谢 。
提交文稿 | |||||||||||||||||||||||||||||
是否OA开放访问 | No | |||||||||||||||||||||||||||||
通讯方式 | AMER SOC HEMATOLOGY, 1900 M STREET. NW SUITE 200, WASHINGTON, USA, DC, 20036 | |||||||||||||||||||||||||||||
出版商 | American Society of Hematology | |||||||||||||||||||||||||||||
涉及的研究方向 | 医学-血液学 | |||||||||||||||||||||||||||||
出版国家或地区 | UNITED STATES | |||||||||||||||||||||||||||||
出版语言 | English | |||||||||||||||||||||||||||||
出版周期 | Semimonthly | |||||||||||||||||||||||||||||
出版年份 | 1946 | |||||||||||||||||||||||||||||
年文章数 | 435点击查看年文章数趋势图 | |||||||||||||||||||||||||||||
Gold OA文章占比 | 35.93% | |||||||||||||||||||||||||||||
研究类文章占比: 文章 ÷(文章 + 综述) | 85.98% | |||||||||||||||||||||||||||||
WOS期刊JCR分区 ( 2024-2025年最新版) | WOS分区等级:1区
| |||||||||||||||||||||||||||||
中国科学院《国际期刊预警 名单(试行)》名单 | 2025年03月发布的2025版:不在预警名单中 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 | |||||||||||||||||||||||||||||
中国科学院期刊分区 ( 2025年3月最新升级版) | 点击查看中国科学院期刊分区趋势图
| |||||||||||||||||||||||||||||
中国科学院期刊分区 ( 2023年12月升级版) |
| |||||||||||||||||||||||||||||
中国科学院期刊分区 ( 2022年12月旧的升级版) |
| |||||||||||||||||||||||||||||
SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0006-4971%5BISSN%5D | |||||||||||||||||||||||||||||
平均审稿速度 | 网友分享经验: 平均1.0个月 | |||||||||||||||||||||||||||||
平均录用比例 | 网友分享经验: 较难 | |||||||||||||||||||||||||||||
LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在BLOOD顺利发表。
快看看作者怎么说吧:服务好评(1篇) 论文致谢 。 提交文稿 | |||||||||||||||||||||||||||||
期刊常用信息链接 |
|
|
|
|
中国学者近期发表的论文 | |
1. | A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or-dependent chronic GVHD Author: Zhao, Yanmin M.; Luo, Yi; Shi, Jimin M.; Wang, Shunqing Q.; Wang, Caixia K.; Jiang, Erlie L.; Liang, Chen; Zhu, Xiaoyu Y.; Zhang, Xuejun J.; Meng, Fankai K.; Jin, Hua; Zhao, Yeqian Q.; Yu, Jian; Lai, Xiaoyu Y.; Liu, Lizhen Z.; Fu, Huarui R.; Ye, Yishan S.; Zhang, Congxiao X.; Wang, Tao; Tu, Lifan F.; Wang, Xunqiang Q.; Huang, He Journal: BLOOD. 2025; Vol. 145, Issue 24, pp. 2857-2872. DOI: 10.1182/blood.2024026581 PubMed DOI |
2. | Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study Author: Kuter, David J.; Ghanima, Waleed; Cooper, Nichola; Liebman, Howard A.; Zhang, Lei; Hu, Yu; Miyakawa, Yoshitaka; Homenda, Wojciech; Galindo, Luisa Elena Morales; Basquiera, Ana Lisa; Tan, Chuen Wen; Saydam, Guray; Huetter-Kroenke, Marie Luise; Chai-Adisaksopha, Chatree; Gomez-Almaguer, David; Tran, Huy; Shin, Ho-Jin; Junior, Ademar Dantas da Cunha; Lazar, Zsolt; Izquierdo, Cristina Pascual; Kirgner, Ilya; Lucchini, Elisa; Kuzmina, Ganna; Fillitz, Michael; Audia, Sylvain; Taparia, Minakshi; Cordoba, Matias; Diab, Remco; Yao, Mengjie; Gouia, Imene; Lee, Michelle; Daak, Ahmed Journal: BLOOD. 2025; Vol. 145, Issue 24, pp. 2914-2926. DOI: 10.1182/blood.2024027336 PubMed DOI |
3. | Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome Author: Chen, Changya; Xu, Jason; Sussman, Jonathan H.; Vincent, Tiffaney; Tumulty, Joseph S.; Yoshimura, Satoshi; Alikarami, Fatemeh; Yu, Wenbao; Ding, Yang-yang; Chen, Chia-hui; Li, Elizabeth Y.; Yang, Austin; Qin, Xiaohuan; Bandyopadhyay, Shovik; Peng, Jacqueline; Polonen, Petri; Newman, Haley; Wood, Brent L.; Hu, Jianzhong; Shraim, Rawan; Hughes, Andrew D.; Diorio, Caroline; Uppuluri, Lahari; Shi, Gongping; Ryan, Theresa; Fuller, Tori; Loh, Mignon L.; Raetz, Elizabeth A.; Hunger, Stephen P.; Pounds, Stanley B.; Mullighan, Charles G.; Frank, David; Yang, Jun J.; Bernt, Kathrin M.; Teachey, David T.; Tan, Kai Journal: BLOOD. 2025; Vol. 145, Issue 23, pp. 2685-2700. DOI: 10.1182/blood.2024027270 PubMed DOI |
4. | Advances in RNA editing in hematopoiesis and associated malignancies Author: Pu, Shuangshuang; Cheng, Tao; Cheng, Hui Journal: BLOOD. 2025; Vol. 145, Issue 21, pp. 2424-2438. DOI: 10.1182/blood.2024027379 PubMed DOI |
5. | N-homocysteinylation of β-arrestins biases GPCR signaling and promotes platelet activation Author: Zheng, Zhong-Yuan; He, Qing-Tao; Yang, Zhao; Zhang, Long; Chen, Nan; Yang, Fan; Jia, Ying-Li; Zhao, Shi-Min; Zhou, De-Min; Wang, Chu; Wang, Xian; Sun, Jin-Peng; Tie, Lu; Zhang, Lin-Qi; Che, Chang-Xiao; Du, Ya-Qin; Han, Lu-Lu; Wang, Jia-Le; Zhang, Chen-Yu; Huang, Shen-Ming Journal: BLOOD. 2025; Vol. 145, Issue 20, pp. 2374-2389. DOI: 10.1182/blood.2024025593 PubMed DOI |
6. | GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia Author: Alikarami, Fatemeh; Xie, Hongbo M.; Riedel, Simone S.; Goodrow, Haley T.; Barrett, Declan R.; Mahdavi, Leila; Lenard, Alexandra; Chen, Changya; Yamauchi, Taylor; Danis, Etienne; Cao, Zhendong; Tran, Vu L.; Jung, Mabel Minji; Li, Yapeng; Huang, Hua; Shi, Junwei; Tan, Kai; Teachey, David T.; Bresnick, Emery H.; Neff, Tobias A.; Bernt, Kathrin M Journal: BLOOD. 2025; Vol. 145, Issue 19, pp. 2179-2195. DOI: 10.1182/blood.2024025761 PubMed DOI |
7. | Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma Author: Yang, Qin; Zhu, Yinghong; Jian, Xingxing; Qiu, Yi; Zhu, Yan; Zhao, Lia; He, Yanjuan; An, Gang; Qiu, Lugui; Guo, Jiaojiao; He, Nihan; Abudumijiti, Huerxidan; Hu, Cong; Chen, Xun; Huang, Siqing; Feng, Xiangling; Li, Xin; Liu, Jing; Xu, Yajing; Zhou, Wen Journal: BLOOD. 2025; Vol. 145, Issue 17, pp. 1876-1889. DOI: 10.1182/blood.2024025694 PubMed DOI |
8. | Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL Author: Zhang, Weina; Cai, Jiaoyang; Wang, Xiang; Ma, Yani; Zhu, Xiaofan; Yu, Jie; Xiao, Peifang; Gao, Ju; Fang, Yongjun; Liang, Changda; Li, Xue; Zhou, Fen; Zhai, Xiaowen; Xu, Xiaoxiao; Tian, Xin; Liu, Aiguo; Wang, Ningling; Zhu, Jiashi; Wang, Lingzhen; Cheng, Frankie Wai-Tsoi; Yang, Liangchun; Zhang, Ge; Cheng, Cheng; Yang, Jun J.; Shen, Shuhong; Li, Chi-kong; Li, Benshang; Jiang, Hua; Pui, Ching-Hon Journal: BLOOD. 2025; Vol. 145, Issue 17, pp. 1890-1902. DOI: 10.1182/blood.2024026381 PubMed DOI |
9. | Efficacy and safety of daratumumab in intermediate/ of CENTAURUS Author: Landgren, Ola; Chari, Ajai; Cohen, Yael C.; Spencer, Andrew; Voorhees, Peter M.; Sandhu, Irwindeep; Jenner, Matthew W.; Smith, Dean; Cavo, Michele; van de Donk, Niels W. C. J.; Beksac, Meral; Moreau, Philippe; Goldschmidt, Hartmut; Vieyra, Diego; Sha, Linlin; Li, Liang; Rousseau, Els; Dennis, Robyn; Carson, Robin; Hofmeister, Craig C Journal: BLOOD. 2025; Vol. 145, Issue 15, pp. 1658-1669. DOI: 10.1182/blood.2024025897 PubMed DOI |
10. | A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/ refractory B-cell non-Hodgkin lymphoma Author: Yu, Wenjuan; Li, Ping; Zhou, Lili; Yang, Min; Ye, Shiguang; Zhu, Dan; Huang, Jiaqi; Yao, Xin; Zhang, Yan; Li, Lanfang; Zhao, Jing; Zhu, Kevin; Li, Jing; Zheng, Chengxiao; Lan, Liping; Wan, Hui; Yao, Yihong; Zhang, Huilai; Zhou, Daobin; Jin, Jie; Liang, Aibin Journal: BLOOD. 2025; Vol. 145, Issue 14, pp. 1526-1535. DOI: PubMed |
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2025 中国: LetPub上海 网站备案号:沪ICP备10217908号-1 沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)
增值电信业务经营许可证:沪B2-20211595 网络文化经营许可证:沪网文[2023]2004-152号
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室